People

Julia's practice focuses on complex patent litigation, particularly in the biotechnology and pharmaceutical industries.  She has experience litigating cases under the Hatch-Waxman Act and Biologics Price Competition and Innovation Act ("BPCIA"), including analyzing complex patent portfolios on biologic products, and providing strategic advice through the steps of the BPCIA patent dance.

Julia is based in King and Spalding's New York office where she works with a team of attorneys representing life sciences companies in patent litigation involving small molecule and biologic products.  She has represented clients in matters relating to biosimilar antibody and insulin products, and relating to an oral treatment for the dermatology condition, rosacea.

Julia received her J.D. from the University of California, Berkeley, School of Law in 2013, where she earned a certificate in intellectual property.  While in law school, she served as a submissions editor for the Berkeley Technology Law Journal and represented clients in affirmative asylum petitions through the California Asylum Representation Clinic.  Prior to law school, Julia worked for two years in academic research labs at the University of California, San Francisco, studying enzyme localization in neurons and microRNA biology.  Julia graduated with a B.S. in Biological Sciences, with honors, from Stanford University in 2008.

Full Bio

Credentials

J.D., University of California, Berkeley, School of Law

B.S. Biological Sciences, Stanford University

California

New Jersey

New York

U.S. Patent and Trademark Office

Matters

Representing Galderma in Hatch-Waxman litigation relating to Oracea®, a once-daily doxycycline product used to treat rosacea

Represented pharmaceutical company in BPCIA litigation regarding biosimilar to monoclonal antibody product, Humira®

Represented pharmaceutical company in patent litigation concerning insulin glargine product

Icon close

Close

Matters

Representing Galderma in Hatch-Waxman litigation relating to Oracea®, a once-daily doxycycline product used to treat rosacea

Represented pharmaceutical company in BPCIA litigation regarding biosimilar to monoclonal antibody product, Humira®

Represented pharmaceutical company in patent litigation concerning insulin glargine product

Matters

Representing Galderma in Hatch-Waxman litigation relating to Oracea®, a once-daily doxycycline product used to treat rosacea

Represented pharmaceutical company in BPCIA litigation regarding biosimilar to monoclonal antibody product, Humira®

Represented pharmaceutical company in patent litigation concerning insulin glargine product

Icon close

Close

Matters

Representing Galderma in Hatch-Waxman litigation relating to Oracea®, a once-daily doxycycline product used to treat rosacea

Represented pharmaceutical company in BPCIA litigation regarding biosimilar to monoclonal antibody product, Humira®

Represented pharmaceutical company in patent litigation concerning insulin glargine product

Credentials

J.D., University of California, Berkeley, School of Law

B.S. Biological Sciences, Stanford University

California

New Jersey

New York

U.S. Patent and Trademark Office